HER2/neu and Ki-67 Expression Predict Non-Invasive Recurrence Following Breast-Conserving Therapy for Ductal Carcinoma in Situ

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2012.41
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Semi‑automated Evaluation of Ki‑67 Index in Invasive Ductal Carcinoma of the Breast

Oncology Letters
Cancer ResearchOncology
2013English

The Role of HER2/neu Overexpression/Amplification in the Progression of Ductal Carcinoma in Situ to Invasive Carcinoma of the Breast

Modern Pathology
Forensic MedicinePathology
2002English

Identification of Aberrant Gene Expression During Breast Ductal Carcinoma in Situ Progression to Invasive Ductal Carcinoma

Journal of International Medical Research
BiochemistryMedicineCell Biology
2019English

Immunohistochemical Expression of Ki-67 in Invasive Breast Carcinoma and Its Correlation With Prognostic Parameters

International Journal of Medical Research and Review
2016English

The Association of Surgical Margins and Local Recurrence in Women With Ductal Carcinoma in Situ Treated With Breast-Conserving Therapy: A Meta-Analysis

Annals of Surgical Oncology
OncologySurgery
2016English

Resistance to Trastuzumab in HER2-Positive Mucinous Invasive Ductal Breast Carcinoma

Clinical Breast Cancer
Cancer ResearchOncology
2013English

Breast Ductal Carcinoma in Situ

International Journal of Surgical Oncology
SurgeryOncology
2012English

Gene Expression Differences Between Ductal Carcinoma in Situ With and Without Progression to Invasive Breast Cancer

American Journal of Pathology
Forensic MedicinePathology
2017English

Clinical Relevance of Coexistence of Ductal Ca in Situ and Invasive Ductal Carcinoma of Breast

Journal of Evidence Based Medicine and Healthcare
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy